Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Alltest Biotech CoSHSE:688606 +4.25%59 ROC (Joel Greenblatt) % is 7.26% as of Mar. 2026, which is 91% below its 10-year median of 84.24. GuruFocus rates SHSE:688606 with a GF Score™ of 59/100 and a GF Value™ of ¥89.34 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Hangzhou Alltest Biotech Co ranks better than 66.99% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Hangzhou Alltest Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.26%.
The historical rank and industry rank for Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:688606'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 18.23 Med: 84.24 Max: 511.73
Current: 18.23
During the past 10 years, Hangzhou Alltest Biotech Co's highest ROC (Joel Greenblatt) % was 511.73%. The lowest was 18.23%. And the median was 84.24%.
SHSE:688606's ROC (Joel Greenblatt) % is ranked better than 66.99% of 836
companies
in the Medical Devices & Instruments industry
Industry Median: 4.86
vs SHSE:688606: 18.23
Hangzhou Alltest Biotech Co (SHSE:688606) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Alltest Biotech Co ROC (Joel Greenblatt) % Chart
SHSE:688606 vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % falls into.
Hangzhou Alltest Biotech Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 7.26% mean?
Hangzhou Alltest Biotech Co (SHSE:688606) has a ROC (Joel Greenblatt) % of 7.26% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hangzhou Alltest Biotech Co and its competitors. This is 91% below median its historical median of 84.24. Over the past decade, Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % has ranged from 18.23 to 511.73. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #276 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 33%.
Is Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % too high?
Hangzhou Alltest Biotech Co's current ROC (Joel Greenblatt) % of 7.26% is 91% below median its 10-year median of 84.24. Over the past 10 years, this metric has ranged from a low of 18.23 to a high of 511.73. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.86. Hangzhou Alltest Biotech Co's value of 7.26% is 49.4% above this industry median. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #276 out of 836 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #276 out of 836 companies for ROC (Joel Greenblatt) %. This puts Hangzhou Alltest Biotech Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.86. Hangzhou Alltest Biotech Co's value of 7.26% is 49.4% above this benchmark. Historically, Hangzhou Alltest Biotech Co's own ROC (Joel Greenblatt) % has ranged from 18.23 to 511.73 over the past decade. While the company's 10-year median is 84.24 vs. the industry median of 4.86, Hangzhou Alltest Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.86, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Alltest Biotech Co's current ROC (Joel Greenblatt) % of 7.26% is 49.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hangzhou Alltest Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Alltest Biotech Co's current ROC (Joel Greenblatt) % is 7.26%, which is 91% below median its own 10-year median of 84.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥89.34, compared to a current price of ¥49.30 — trading 44.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 7.26%, which is 91% below median its 10-year median of 84.24 and 49.4% above the Medical Devices & Instruments industry median of 4.86. Hangzhou Alltest Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current ROC (Joel Greenblatt) % is 7.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥49.30 is trading 44.8% below its estimated GF Value™ of ¥89.34.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
ROC (Joel Greenblatt) %: 7.26% (91% below median its 10-year median of 84.24)
GF Value™: ¥89.34 vs. price of ¥49.30 (44.8% below fair value)
Industry Position: 49.4% above the Medical Devices & Instruments median (#276 of 836)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
